The CEO and President of R&D selling on the same day is a modest caution flag against the overwhelmingly bullish analyst consensus. Monitor for any upcoming clinical data readouts or pipeline updates that could explain the timing. The dollar amount is too small to be a strong bearish signal, but the cluster nature and seniority of sellers warrant watching the next 8-K or press release for context.
RLAY drugs
RLAY drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK BELOW ENTRY AT T+20- T+0 · Sep 10 $18.89entry
- T+1 · 2mo ago −0.11%α −0.96% · $18.87
- T+5 · 2mo ago +1.59%α +0.96% · $19.19
- T+20 · 6w ago −7.83%α −10.21% · $17.41
- T+47 · todayOpen
- T+60 · in 17d Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Two top executives at Relay Therapeutics, CEO Sanjiv Patel and President of R&D Donald Bergstrom, sold a combined $1.07M in open-market sales on September 8, 2026. While the dollar amount is modest relative to the $4.2B market cap (~0.03%), the cluster involves the CEO and President of R&D selling on the same day, which warrants attention. The stock has a 95% analyst buy rating and strong institutional support, but the insider sales introduce a note of caution against the bullish consensus.
Key Financial Metrics
Key Facts
- CEO Sanjiv Patel sold 48,199 shares at $18.94 for $912,889 on September 8, 2026.
- President of R&D Donald Bergstrom sold 8,530 shares at $18.97 for $161,814 on September 8, 2026.
- CFO Thomas Catinazzo also sold 17,717 shares at $18.94 for $335,560 on September 8, 2026.
- Total cluster value is $1.07M, representing approximately 0.03% of the $4.2B market cap.
- The stock has 95% analyst buy rating (19 Buy/Strong Buy, 1 Hold, 0 Sell).
- Institutional 13F shows strong accumulation: 11 adds, 6 doubled positions, only 2 trims.
Financial Impact
Insider sales of $1.07M represent 0.03% of market cap, trivial in absolute size but notable for involving the CEO and President of R&D on the same day.
Risk Factors
- Insider sales by CEO and President of R&D could signal reduced conviction ahead of upcoming pipeline milestones.
- The stock's high valuation (95% analyst buy rating) leaves limited upside if clinical data disappoints.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CLUSTER Data (Synthetic) | cluster-RLAY-1789030928152 |
Track record
21 reports on RLAY
6 of 10 bullish or bearish reports moved the stock their way by T+60. Best: +65.12% at T+60 after the May 19, 2026 report. 8 of 11 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Neutral 3/10 Entry price pending
- Nov 16, 2026today SC 13G Neutral 4/10 Entry $17.68 Now $17.27 −2.29% settles Feb 12
- Nov 4, 202612d ago 8-K Neutral 4/10 No price data
- Nov 4, 202612d ago Press Release Neutral 4/10 Entry $17.00 Now $17.27 +1.59% settles Feb 3
- Nov 3, 202613d ago Institutional Cluster Neutral 2/10 Entry $17.44 Now $17.27 −0.97% settles Feb 1
- Oct 7, 20265w ago 144 Neutral 2/10 Entry $17.41 Now $17.27 −0.80% settles Jan 5
- Oct 6, 20265w ago 144 Neutral 3/10 Entry $17.95 Now $17.27 −3.79% settles Jan 4
- Sep 9, 20269w ago Insider Cluster Neutral 4/10 Viewing Entry $18.89 Now $17.27 −8.58% settles Dec 4
- Aug 28, 202611w ago Insider Cluster Bearish 6/10 Entry $18.77 Now $17.27 +7.99% settles Nov 23
- Aug 18, 202612w ago Insider Cluster Bearish 5/10 Entry $20.74 to $19.72 Now $17.27 +16.73% ▲ +4.92% +4.09% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers